These findings are in accordance with the study by Yang et al., who further explored messenger RNA level of KRAS in different cancer types using the Oncomine database and found that KRAS was highly expressed in breast cancer, kidney cancer, lung cancer, myeloma, ovarian cancer, pancreatic cancer, and sarcoma compared to normal samples18. Here, KRAS is linked to ovarian cancer.